Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor

被引:15
作者
Borkow, G
Salomon, H
Wainberg, MA
Parniak, MA
机构
[1] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, AIDS Ctr, Sir Mortimer B Davis Jewish Hosp, Montreal, PQ H3T 1E2, Canada
关键词
D O I
10.1089/088922202760072339
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Short exposure of uninfected lymphocytes to UC781, a tight-binding nonnucleoside reverse transcriptase inhibitor (NNRTI), renders these cells refractory to subsequent HIV infection in the absence of exogenous drug (Borkow et al: J Virol 1997;71:3023-3030). Since epithelial cells may play a role in the sexual transmission of HIV-1, we examined the ability of NNRTI pretreatment to protect ME180 cervical epithelial cells and 1407 intestinal epithelial cells from subsequent HIV-1 infection. Epithelial cells were pretreated with NNRTI, then exposed to HIV-1 chronically infected 1191 cells for a short time following removal of the exogenous drug. The epithelial cells were productively infected by HIV-1, as shown by the presence of integrated HIV-1 proviral DNA, the presence of intracellular p24 antigen, and the production of nascent HIV-1 virions (cell-free p24) at various times postinfection. UC781 pretreatment of the epithelial cells did not prevent HIV-1 infection, since the cells had integrated proviral DNA, but the infectivity of virus subsequently produced from the UC781-treated cells was attenuated in a dose-dependent manner and virtually abolished at UC781 concentrations readily attainable in vivo. In contrast, nevirapine was ineffective in this respect, suggesting that not all NNRTI have microbicidal potential. The abrogation of infectivity of virus produced from UC781-pretreated epithelial cells suggests that this NNRTI may be useful in vaginal microbicide formulations targeted to inhibit HIV-1 in the vaginal/cervical or rectal milieus of a newly exposed individual.
引用
收藏
页码:711 / 714
页数:4
相关论文
共 17 条
[1]   Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent [J].
Balzarini, J ;
Naesens, L ;
Verbeken, E ;
Laga, M ;
Van Damme, L ;
Parniak, M ;
Van Mellaert, L ;
Anné, J ;
De Clercq, E .
AIDS, 1998, 12 (10) :1129-1138
[2]  
Balzarini J, 1996, MOL PHARMACOL, V50, P394
[3]   The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase [J].
Barnard, J ;
Borkow, G ;
Parniak, MA .
BIOCHEMISTRY, 1997, 36 (25) :7786-7792
[4]   Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: Retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase [J].
Borkow, G ;
Barnard, J ;
Nguyen, TM ;
Belmonte, A ;
Wainberg, MA ;
Parniak, MA .
JOURNAL OF VIROLOGY, 1997, 71 (04) :3023-3030
[5]  
BOURINBAIAR AS, 1991, J ACQ IMMUN DEF SYND, V4, P56
[6]   Transmission of HIV-1 variants resistant to the three classes of antiretroviral agents:: implications for HIV therapy in primary infection [J].
Colson, P ;
Ravaux, I ;
Yahi, N ;
Tourrès, C ;
Gallais, H ;
Tamalet, C .
AIDS, 2002, 16 (03) :507-509
[7]   PATHOGENESIS OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
LEVY, JA .
MICROBIOLOGICAL REVIEWS, 1993, 57 (01) :183-289
[8]   SLOWING THE SPREAD OF HIV - AGENDA FOR THE 1990S [J].
MERSON, MH .
SCIENCE, 1993, 260 (5112) :1266-1268
[9]  
NKOWANE BM, 1991, AIDS, V5, pS7
[10]  
Parniak M. A., 1997, International Antiviral News, V5, P205